443 completed, 303 unknown, 165 recruiting, 116 terminated. 1200 Phase 2, 266 Phase 1, 67 Phase 3.
Follow Stomach Diseases: new trials by email Literature Review of Stomach Diseases trials Research Report on Stomach Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction Adenocarcinoma Serplulimab, Docetaxel, Oxaliplatin, S1, and Lenvatinib combined with PIPAC - Gastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal Metastasis | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 42 | 2026-12-15 | 2026-10-29 |
| A Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Refractory to ≥ Second-Line Chemotherapy TAS102+Nedaplatin - Gastric Cancer (GC) | Phase 2 | Not yet recruiting | Tao Zhang | 36 | 2026-12-01 | 2026-11-03 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| Application of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal Metastasis Retlirafusp alfa + nab-paclitaxel + apatinib, HEPIC - Gastric Cancer (Diagnosis) | Phase 2 | Not yet recruiting | Anhui Provincial Cancer Hospital | 32 | 2026-11-20 | 2026-10-29 |
| GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer Neoadjuvant chemotherapy, Olanzapine - Gastric Adenocarcinoma, Gastric Cancer | Phase 2 | Recruiting | University of Illinois Chicago | 26 | 2026-11-03 | 2026-11-09 |
| Use of Pyrvinium to Reverse Stomach Precancerous Conditions Placebo, Pyrvinium, Blood biomarkers analyses - STOMACH NEOPLASM | Phase 2 | Not yet recruiting | National University Hospital, Singapore | 50 | 2026-11-01 | 2026-10-13 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors. SYS6062 - Advanced Solid Tumors, Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 260 | 2026-11-01 | 2026-10-27 |
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer Gastrectomy with D2 lymphadenectomy plus para-aortic lymph node dissection, Gastrectomy with standard D2 lymphadenectomy - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 32 | 2026-11-01 | 2026-11-03 |
| Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer Short course radiation therapy, Standard of care neoadjuvant chemotherapy - Gastric Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 20 | 2026-10-31 | 2026-08-06 |
| A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy Trastuzumab + Durvalumab + FLOT - Gastric Cancer | Phase 2 | Recruiting | Samsung Medical Center | 20 | 2026-10-06 | 2026-11-02 |
| Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) - Colorectal Cancer, Gastric Cancers | Phase 2 / Phase 3 | Recruiting | GE Healthcare | 175 | 2026-10-01 | 2026-06-17 |
| A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer Fruquintinib, Sintilimab, Irinotecan Hydrochloride Liposome Injection (II) - Stomach Neoplasms, Gastric Cancer | Phase 2 | Not yet recruiting | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | 20 | 2026-10-01 | 2026-09-14 |
| Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJC Retlirafusp alfa, zeprumetostat, apatinib - Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Fudan University | 55 | 2026-10-01 | 2026-10-14 |
| Evaluation of XYA02 in Patients With Advanced Solid Tumors XYA02 - MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | XYone Therapeutics, Inc | 190 | 2026-09-17 | 2026-09-25 |
| Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) Stereotactic Body Radiation Therapy (SBRT), Pembrolizumab, Nivolumab - Head and Neck Cancer, Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Mark Bernard | 35 | 2026-09-09 | 2026-10-14 |
| A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma Intratumoral 2141-V11, Nivolumab, Fluoropyrimidine - Esophageal Cancer, Advanced Esophageal Cancer | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2026-09-04 | 2026-09-14 |
| Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study Ferrous succinate, Ferrous Sulfate, Serplulimab - Gastric Neoplasms | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 54 | 2026-09-01 | 2026-10-14 |
| Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma Retlirafusp Alfa, Oxaliplatin, Capecitabine - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Tang-Du Hospital | 21 | 2026-08-30 | 2026-07-17 |
| SL-28 for Advanced Solid Tumours SL-28 - Head & Neck Cancer, Pancreas Carcinoma | Phase 1 / Phase 2 | Recruiting | Second Life Therapeutics | 60 | 2026-08-14 | 2026-09-15 |
Showing 20 of 1200. Sign in to see all of them.
Stomach Neoplasms (1084) · Esophageal Neoplasms (186) · Colorectal Neoplasms (100) · Pancreatic Neoplasms (91) · Carcinoma, Non-Small-Cell Lung (75) · Neoplasm Metastasis (70) · Ovarian Neoplasms (70) · Breast Neoplasms (67) · Adenocarcinoma Of Esophagus (63) · Neoplasms (56) · Gastroparesis (50) · Lung Neoplasms (46) · Melanoma (45) · Carcinoma, Hepatocellular (43) · Uterine Cervical Neoplasms (41)
Digestive System Diseases (1195) · Gastrointestinal Diseases (1193) · Digestive System Neoplasms (1087) · Neoplasms by Site (1085) · Gastrointestinal Neoplasms (1066) · Neoplasms (1043) · Neoplasms by Histologic Type (211) · Esophageal Diseases (198) · Head and Neck Neoplasms (190) · Neoplasms, Glandular and Epithelial (181) · Pathological Conditions, Signs and Symptoms (173) · Endocrine System Diseases (163) · Intestinal Diseases (162) · Carcinoma (155)
Oxaliplatin (205) · Capecitabine (139) · Fluorouracil (115) · Docetaxel (112) · Cisplatin (102) · S 1 (combination) (99) · Paclitaxel (84) · Leucovorin (78) · Irinotecan (69) · pembrolizumab (65) · Trastuzumab (49) · sintilimab (43) · apatinib (41) · Nivolumab (38) · Bevacizumab (26)
Fudan University (29) · National Cancer Institute (NCI) (27) · Memorial Sloan Kettering Cancer Center (19) · The First Affiliated Hospital with Nanjing Medical University (19) · Yonsei University (17) · AstraZeneca (15) · Asan Medical Center (14) · Tianjin Medical University Cancer Institute and Hospital (14) · Chinese Academy of Medical Sciences (13) · National Cancer Center, Korea (13) · Peking University (13) · Samsung Medical Center (13) · Sun Yat-sen University (13) · Hoffmann-La Roche (11) · Ruijin Hospital (11)
China (385) · United States (378) · South Korea (180) · Japan (76) · Germany (75) · Spain (72) · United Kingdom (71) · France (68) · Canada (63) · Taiwan (63) · Italy (56) · Australia (52) · Belgium (43) · Singapore (32) · Netherlands (29)
Yelena Janjigian, MD (7) · Aminah Jatoi, MD (4) · Jaffer Ajani, MD (4) · Peter Enzinger, MD (4) · Wei Peng Yong, MRCP, MB ChB (4)
PMID 35623069, PMID 40340830, PMID 40341124, PMID 15273542, PMID 20728210, PMID 21444866, PMID 22189752, PMID 23848826, PMID 30566590, PMID 30911859, PMID 30982686, PMID 31513484, PMID 32301137, PMID 33792646, PMID 35219300, PMID 37963317, PMID 38421211, PMID 41811823, PMID 10089184, PMID 10091726, PMID 10400410, PMID 10581077, PMID 10811496, PMID 11091234, PMID 11223832, PMID 11248153, PMID 11289756, PMID 11413430, PMID 11556297, PMID 11712875, PMID 11754382, PMID 11813623, PMID 12074329, PMID 12378346, PMID 12454110, PMID 12680184, PMID 12794247, PMID 1334988, PMID 14578723, PMID 14578729, PMID 15234753, PMID 15533252, PMID 15542799, PMID 15650632, PMID 15668283, PMID 15783049, PMID 1579757, PMID 15865075, PMID 15928658, PMID 1598671
2023 (12), 2017 (7), 2014 (6), 2025 (6), 2016 (5), 2018 (5), 2009 (4), 2019 (4), U10CA032102 (4), 2008 (3), 2015 (3), P30CA016087 (3), 2005 (2), N01CM00038 (2), N01CM62204 (2)